9月8日 - ** 生物技术公司 Pulse Biosciences PLSE.O 股价盘前上涨 6.4% 至 16.08 美元
** 该公司称，美国食品和药物管理局（FDA）已批准该公司测试其治疗心房颤动或心律不齐的心脏设备。
** 该研究计划招募多达 136 名患者，旨在测试名为纳秒脉冲场消融术的设备的有效性。
** 该设备用于在心脏手术中进行连续消融
** 截至上次收盘，股价累计下跌 13.2
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.